A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia

Claudia Trenkwalder, Daniela Berg, Olivier Rascol, Karla Eggert, Andres Ceballos-Baumann, Jean Christophe Corvol, Alexander Storch, Lin Zhang, Jean Philippe Azulay, Emmanuel Broussolle, Luc Defebvre, Christian Geny, Michal Gostkowski, Fabrizio Stocchi, Christine Tranchant, Pascal Derkinderen, Franck Durif, Alberto J. Espay, Andrew Feigin, Jean Luc HouetoJohannes Schwarz, Thérèse Di Paolo, Dominik Feuerbach, Hans Ulrich Hockey, Judith Jaeger, Annamaria Jakab, Donald Johns, Gurutz Linazasoro, Paul Maruff, Izabela Rozenberg, Judit Sovago, Markus Weiss, Baltazar Gomez-Mancilla

Research output: Contribution to journalArticlepeer-review

Abstract

Background: This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease and levodopa-induced dyskinesia. Methods: Patients with idiopathic Parkinson's disease and moderate to severe levodopa-induced dyskinesia were randomized to AQW051 10 mg (n = 24), AQW051 50 mg (n = 24), or placebo (n = 23) once daily for 28 days. Coprimary end points were change in Modified Abnormal Involuntary Movement Scale and Unified Parkinson's Disease Rating Scale part III scores. Secondary outcomes included pharmacokinetics. Results: In total, 67 patients completed the study. AQW051-treated patients experienced no significant improvements in Modified Abnormal Involuntary Movement Scale or Unified Parkinson's Disease Rating Scale part III scores by day 28. AQW051 was well tolerated; the most common adverse events were dyskinesia, fatigue, nausea, and falls. Conclusions: AQW051 did not significantly reduce dyskinesia or parkinsonian severity.

Original languageEnglish
Pages (from-to)1049-1054
Number of pages6
JournalMovement Disorders
Volume31
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Keywords

  • AQW051
  • dyskinesias
  • levodopa (l-dopa)
  • nicotinic acetylcholine receptor agonist (nAChR) α7
  • Parkinson's disease

ASJC Scopus subject areas

  • Medicine(all)
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia'. Together they form a unique fingerprint.

Cite this